U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07261345) titled 'Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease' on Nov. 23.
Brief Summary: Graves' disease is an autoimmune thyroid disorder in which autoantibodies against the thyroid-stimulating hormone receptor (TRAb) lead to excessive thyroid hormone production and systemic complications, as well as thyroid eye disease and pretibial myxedema in some cases. Patients with refractory Graves' disease often fail to achieve durable remission despite prolonged antithyroid medication.
This study aims to evaluate the safety and efficacy of RD06-05, an allogeneic dual CD19/BCMA CAR-T therapy, in participants with refractory Graves' diseas...